New Products/Product News
Knee System
Wright Medical Group, Inc. has announced the launch of the EVOLUTION ™ Medial-Pivot Knee System. The EVOLUTION™ Knee System represents Wright’s next generation in medial-pivot knees.
The new EVOLUTION™ Medial-Pivot Knee System builds upon 12 years of clinical experience with the ADVANCE® Medial-Pivot Knee System. Wright’s medial-pivot technology is designed to replicate the stability and function of the natural knee. Studies have shown that this technology has been preferred consistently by patients who received bilateral knee implants with a medial-pivot design in 1 knee and a traditionally designed implant in the other knee.
Inspired by this patient preference, Wright created the EVOLUTION™ Knee System to enhance its medial-pivot technology by offer ing more sizing opt ions, improved instrumentation, and a medial-pivoting posterior stabilized option. These enhancements were achieved through stateof- the-art engineering concepts and manufacturing technologies, including the use of computed tomography to produce implants that more accurately replicate natural knee anatomy and contain features that aid in implantation through less-invasive surgical exposures. The resulting EVOLUTION™ Knee System is designed to ease rehabilitation and address stability concerns that may be experienced by some total knee replacement recipients.
To learn more, contact
Wright Medical Technology, Inc.
5677 Airline Road
Arlington, TN 38002;
phone (800) 238-7117
fax (901) 867-9534
www.wmt.com
Vessel Cover
Xylos Corporation has announced receiving 510(k) clearance from the US FDA for its Xylos® Vessel Guard. This implantable device is indicated as a cover for vessels during anterior vertebral surgery. Xylos now has achieved a total of six 510(k) clearances for surgical implants based on its biomaterial platform.
For more information, contact
Xylos Corporation
838 Town Center Drive,
Langhorne, PA 19047
phone (215) 867-0220
www.xyloscorp.com
New Biologic Bone Graft Product
The US FDA Orthopaedic and Rehabilitation Devices Panel voted 9 for and 4 against (1 abstention) on safety, and 10 for and 3 against (1 abstention) on effectiveness, that data— including results from a large, prospective, randomized, clinical trial—demonstrated the safety and effectiveness of AMPLIFY™ rhBMP-2 M